Anti-CD20 monoclonal antibody that depletes CD20-positive B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes CD20+ cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
YES
DIRECT
Binds CD20 on B cells and triggers antibody-dependent cellular cytotoxicity via FcγR-expressing effector cells, complement-dependent cytotoxicity/lysis, and can induce apoptosis.
Subcutaneous CD20×CD3 bispecific T‑cell–engaging monoclonal antibody that redirects CD3+ T cells to kill CD20+ malignant B cells.
Humanized bispecific monoclonal antibody that binds CD3 on T cells and CD20 on B cells, cross-linking T cells to malignant B cells to form an immune synapse, activate T cells, and induce targeted T‑cell–mediated cytotoxicity against CD20+ tumor cells.
YES
DIRECT
Mosunetuzumab bridges CD20 on B cells and CD3 on T cells, forming an immune synapse and activating T cells to kill CD20+ cells via perforin/granzyme-mediated cytotoxicity.
Subcutaneous CD20×CD3 bispecific T‑cell–engaging monoclonal antibody that redirects CD3+ T cells to kill CD20+ malignant B cells.
Humanized bispecific monoclonal antibody that binds CD3 on T cells and CD20 on B cells, cross-linking T cells to malignant B cells to form an immune synapse, activate T cells, and induce targeted T‑cell–mediated cytotoxicity against CD20+ tumor cells.
NO
INDIRECT
The drug binds CD3 on T cells to recruit and activate them against CD20+ B cells; activated T cells kill the CD20-expressing targets (perforin/granzyme), not the CD3+ T cells.
A bispecific T-cell engager antibody targeting BCMA and CD3 that redirects T cells to kill BCMA-positive myeloma cells via immune synapse formation and cytokine-mediated cytotoxicity.
Bispecific antibody that simultaneously binds BCMA on myeloma cells and CD3 on T cells, forming an immune synapse that redirects T-cell cytotoxicity and cytokine release to kill BCMA-positive plasma cells.
YES
DIRECT
The bispecific binds BCMA on target cells and CD3 on T cells, forming an immune synapse that activates T-cell cytotoxicity (perforin/granzyme release and cytokine-mediated killing) to lyse BCMA-positive cells.
Anti‑CD20 monoclonal antibody that depletes B cells via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and apoptosis.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on B cells and mediates B‑cell depletion via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and kills them via Fc-mediated ADCC by NK cells/macrophages, complement-dependent cytotoxicity, and apoptosis upon CD20 cross-linking.